Arunjyoti Bio Ventures Other Announcement
Arunjyoti Bio Ventures Limited has changed its corporate name to Pasura Industries Limited, effective September 2, 2026.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
17 announcements
Arunjyoti Bio Ventures Limited has changed its corporate name to Pasura Industries Limited, effective September 2, 2026.
Arunjyoti Bio Ventures Ltd held its 40th Annual General Meeting on August 12, 2026, via video conference. The company disclosed proceedings of the meeting.
Arunjyoti Bio Ventures Ltd. will hold its 40th Annual General Meeting on August 12, 2026, to conduct ordinary business and approve the appointment of secretarial auditors.
Arunjyoti Bio Ventures Ltd has filed its quarterly shareholding pattern for the period ending June 30, 2026, in compliance with SEBI regulations.
Arunjyoti Bio Ventures appointed M/s. Vivek Surana & Associates as Secretarial Auditor for five years. This follows the resignation of M/s. Manoj Parakh & Associates.
Arunjyoti Bio Ventures Ltd reported revenue from operations of ₹8.2 Cr (-5.7% YoY) and net profit of ₹0.6 Cr (-70.0% YoY) for Q1 FY27.
Arunjyoti Bio Ventures Ltd will hold a Board Meeting on July 9, 2026. The agenda includes reviewing un-audited financial results for the quarter ended June 30, 2026.
Arunjyoti Bio Ventures Ltd reported revenue from operations of ₹7.2 Cr (+35.8% YoY) and a net loss of ₹5.4 Cr for Q4 FY26.
Arunjyoti Bio Ventures reported audited FY2026 results and approved a ₹2.74 Crore write-off. The company also corrected a prior period deferred tax error.
Arunjyoti Bio Ventures postponed its May 12 board meeting to May 13, 2026. The meeting will consider audited financial results for the prior fiscal year.
Arunjyoti Bio Ventures Limited has postponed its Board Meeting originally scheduled for May 8, 2026, to May 12, 2026, due to unavoidable reasons. The meeting will consider and approve audited financial results for the quarter and year ended March 31, 2026. The agenda for the meeting remains unchanged.
Arunjyoti Bio Ventures Ltd has scheduled a Board of Directors meeting for May 8, 2026. The board will primarily consider and approve the audited financial results for the quarter and year ended March 31, 2026.
Arunjyoti Bio Ventures Limited has submitted its annual disclosure for FY 2025-26, confirming it does not qualify as a 'Large Corporate' under SEBI debt-raising norms. Consequently, the company has no mandatory requirement to raise incremental borrowings through debt securities.
Arunjyoti Bio Ventures Ltd disclosed that it does not qualify as a 'Large Corporate' under SEBI norms for FY 2026-2027. The company reported outstanding borrowings of ₹20.57 Crore as of March 31, 2026, which is below the ₹1,000 Crore threshold required for the Large Corporate framework.
Chennupati Sarath Kumar sold 54,25,516 equity shares of Arunjyoti Bio Ventures Limited, representing a 2.91% stake, via the open market. This transaction reduced the seller's total holding from 7.57% to 4.66%.
Arunjyoti Bio Ventures Ltd (BSE: 530881) issued a clarification regarding unsolicited messages allegedly being circulated about the company's shares. The company advised investors to exercise due care and caution while dealing in its scrip. This disclosure is made under Regulation 30(11) of SEBI (LODR) Regulations, 2015.
Promoter Chennupati Sarath Kumar sold 60,97,684 equity shares of Arunjyoti Bio Ventures Limited (3.27% stake) via the open market between March 23 and April 10, 2026. Following this sale, the promoter's holding decreased from 10.84% to 7.57% of the company's total equity share capital.